Astra
As of the edition of 20 October 2026, Astra runs 15 drugs, 15 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bupivacaine | none listed | 1 |
| Lidocaine | none listed | 2 |
| Ropivacaine | none listed | 2 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Metoprolol | none listed | 0 |
| Prilocaine | none listed | 2 |
| Retinol | none listed | 0 |
| Chloroprocaine | none listed | 2 |
| Dopamine | none listed | 3 |
| Foscarnet | none listed | 0 |
| Dezocine | none listed | 2 |
| Vitamin a palmitate | none listed | 0 |
| Ritodrine | none listed | 0 |
| Dyclonine | none listed | 2 |
| Etidocaine | none listed | 2 |
A route B row is one company at one target.
Where its trials are
- Immune system: 9 trials led
- Infections: 9 trials led
- Urinary and reproductive: 9 trials led